Collectively, the clinical data support the preclinical findings implicating SFKs in CML progression and imatinib resistance, and suggest that dual SFK/BCR-ABL inhibition may be more effective than inhibition of BCR-ABL alone. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.